#115: Stem Cell Therapy for MS – A Conversation with Prof. Christoph Heesen
In this episode, I speak with Prof. Christoph Heesen from the University Medical Center Hamburg-Eppendorf (UKE) in Germany about stem cell therapy for people with multiple sclerosis. Christoph shares his clinical experience and gives a detailed overview of how the treatment works, who it may benefit, and what risks are involved. We also discuss a […]
#112: MSIF – Past, Present and Future with Peer Baneke and Lydia Makaroff
The Multiple Sclerosis International Federation (MSIF) plays a vital role in uniting the global MS community to improve the lives of people affected by multiple sclerosis. In this inspiring interview, Peer Baneke, former CEO, and Lydia Makaroff, the new CEO, share their insights on past milestones, current challenges, and the future vision of MSIF. From […]
#103: Can epigenetic research transform MS treatment? Insights into DNA methylation and MS progression with Dr. Majid Pahlevan Kakhki
Have you ever wondered how epigenetic mechanisms influence multiple sclerosis (MS) progression and why some people experience rapid disease worsening while others have a milder course? Could there be hidden biological switches beyond genetics affecting MS? In this deep dive, I explore the fascinating world of epigenetics with Dr. Majid Pahlevan Kakhki, uncovering how factors […]
#100: The Future of MS Care. Can Digital Twins Predict Your Disease Progression? With Prof. Tjalf Ziemssen
The concept of a digital twin is revolutionizing medicine, offering a new way to personalize treatments and predict disease progression. But what exactly does it mean for multiple sclerosis patients? In the 100th anniversary episode of the English MS-Perspektive Podcast, Prof. Tjalf Ziemssen, one of the world’s leading MS experts and innovators, explains how AI […]
#069: Beyond Boundaries. Advocacy, Research, and Recognition in MS with Rachel Horne
MS patient and adovcate Rachel Horne sponsors a prize for women in MS research and campaigns for more diversity in clinical trials.
